In NSCLC, immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have shown greater efficacy and lower toxicity compared to chemotherapy [2–4]. Here, PDCD1 is linked to non-small cell lung carcinoma.